About the Company
LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy™ capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $LOGC News
AstraZeneca pays record 660% premium for gene editing company LogicBio
As per the agreement, Alexion will initiate a cash tender offer through a subsidiary to acquire all outstanding shares of LogicBio for $2.07 per share, a rare 660% premium on LogicBio’s share price.
LogicBio Therapeutics to Present New Data on GeneRide™ Platform and Next Generation Capsid Development Program at the Ameri...
LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced ...
Endeavour Silver Stock (NYSE:EXK), Quotes and News Summary
Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion ...
Cognition Therapeutics Inc CGTX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
EFTR eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...
Ovid Therapeutics Inc OVID
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
ONTX Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage ...
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders are probably feeling a little disappointed, since its shares fell 5.9% to US$26.10 in the week after its latest full-year results.
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...
Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a ...
Viking Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...